Genetic Signatures signs up
Wednesday, 22 October, 2008
Privately held Sydney biotech Human Genetic Signatures has signed a licensing agreement with US diagnostics specialist ProGen Tech to develop assays for pathogens such as MRSA and Clostridium difficile.
The assays will be integrated into ProGen Tech’s Entura nucleic acid purification system.
Human Genetic Signatures’ technology is called 3base, which is designed to simplify the genomes of microbial targets to aid detection. The company has also developed a DNA methylation analysis methodology called MethylEasy.
ProGen Tech hopes to present manual assays to the US FDA next year, followed by a fully automated version in 2010.
The equipment is aimed at the molecular and clinical diagnostics markets.
Could this 'nanobone' material allow children to regrow bone?
Australian scientists believe they have found an alternative to invasive bone graft procedures in...
The last mile of life sciences innovation
How do we translate technological possibility into meaningful real-world impact?
Machine learning uncovers patterns in DNA methylation
A new machine-learning method identifies differentially methylated DNA regions without sample...
